How glucagon-like peptide 1 receptor agonists work
In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk...
Main Authors: | Christine Rode Andreasen, Andreas Andersen, Filip Krag Knop, Tina Vilsbøll |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2021-07-01
|
Series: | Endocrine Connections |
Subjects: | |
Online Access: | https://ec.bioscientifica.com/view/journals/ec/10/7/EC-21-0130.xml |
Similar Items
-
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
by: Laurie L. Baggio, et al.
Published: (2021-04-01) -
Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01) -
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
by: Yu Mi Kang, et al.
Published: (2016-06-01) -
Organoprotective effects of glucagon-like peptide-1 receptor agonists with regard to findings of evidencebased cardiovascular safety studies
by: Yu. Sh. Khalimov, et al.
Published: (2020-01-01) -
Glucagon-like peptide-1 receptor agonists, selection within the class. The rational combination of insulin glargine 100 + lixisenatide
by: M. V. Martjanova, et al.
Published: (2020-05-01)